68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis
Andrew X. Zhu, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Kalgi Mody, Tomoki Kubota, Corina E. Dutcus, Kenichi Saito, Abby B. Siegel, Leonid Dubrovsky, Josep M. Llovet
Josep M. Llovet, Karen Shepard, RS Finn, Masafumi Ikeda, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, H. Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Kalgi Mody, Tomoki Kubota, Kenichi Saito, A.B. Siegel, Leonid Dubrovsky, Andrew X. Zhu
Masafumi Ikeda, Max W. Sung, Masatoshi Kudo, Masahiro Kobayashi, Ari David Baron, Richard S. Finn, Shuichi Kaneko, Andrew X. Zhu, Tomoki Kubota, Silvija Kralijevic, Hiroki Ikezawa, Abby B. Siegel, Hiromitsu Kumada, Takuji Okusaka
Masafumi Ikeda, Max W. Sung, Masatoshi Kudo, Masahiro Kobayashi, Ari David Baron, Richard S. Finn, Shuichi Kaneko, Andrew X. Zhu, Tomoki Kubota, Silvija Kralijevic, Hiroki Ikezawa, Abby B. Siegel, Hiromitsu Kumada, Takuji Okusaka
Discussion(0)
No comments yet. Be the first to comment.